6533b7d9fe1ef96bd126cca8
RESEARCH PRODUCT
Overview of the benefitsand potential issues of the nonavalent HPV vaccine
Mario PretiLuciano MarianiPaolo CristoforoniCarlo M. StiglianoAntonio Perinosubject
MaleHPVmedicine.medical_specialtyUterine Cervical NeoplasmsDiseaseAnatomic region03 medical and health sciences0302 clinical medicineHPV nonavalent vaccinePrimary preventionEnvironmental healthmedicineHumansPapillomavirus Vaccines030212 general & internal medicineCervical cancer; HPV; HPV nonavalent vaccine; Prevention; Female; Humans; Male; Papillomaviridae; Papillomavirus Infections; Papillomavirus Vaccines; Randomized Controlled Trials as Topic; Uterine Cervical NeoplasmsPapillomaviridaeRandomized Controlled Trials as TopicGynecologyCervical cancerbusiness.industryPreventionPapillomavirus InfectionsObstetrics and GynecologyHpv vaccinationGeneral Medicinemedicine.disease030220 oncology & carcinogenesisCervical cancer; HPV; HPV nonavalent vaccine; PreventionCervical cancerFemalebusinessdescription
HPV-related diseases affect anogenital and oropharyngeal regions, heavily affecting the psychosexual dimension of both male and female individuals. HPV vaccination programs based on a bivalent or quadrivalent vaccine have opened broad perspectives for primary prevention. A nonavalent HPV vaccine (9vHPV), covering nine genotypes (HPV6, HPV11, HPV16, HPV18, HPV31, HPV33, HPV45, HPV52, and HPV58), might provide further improvement in terms of direct protection. In the present report, efficacy and safety data from 9vHPV vaccine development programs are examined. Efficacy data come from a pivotal trial, which was conducted among women aged 16–26 years randomly assigned to receive either the 9vHPV or the quadrivalent HPV (4vHPV) vaccine. The 9vHPV vaccine was shown to have potential benefits as compared with 4vHPV, increasing the overall estimated rate of prevention to 90% for cervical cancer and up to 80% for precancerous cervical lesions. For all other HPV-related pre-invasive and invasive lesions, 9vHPV showed potentially greater disease reduction, depending on the anatomic region examined. Thus, the 9vHPV vaccine shows clinical potential for the prevention of HPV-related diseases in both sexes. Future adoption of 9vHPV will depend on factors including market price, cost-effectiveness data, use of a two-dose schedule, and safety and efficacy monitoring in real-life programs. This article is protected by copyright. All rights reserved.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2017-01-01 |